Published: 20 March 2023
Author(s): Jon Zubiaur, Alba Herrero-Morant, Adrián Margarida de Castro, Raquel Pérez-Barquín, Ivan Ferraz-Amaro, Javier Loricera, Santos Castañeda, Ricardo Blanco
Issue: June 2023
Section: Original article

Systemic lupus erythematosus (SLE) is a chronic, multisystemic disease with a variable and potentially severe prognostic course [1]. Antimalarial agents, such as chloroquine (CQ) and, mainly, hydroxychloroquine (HCQ) are the cornerstone of SLE treatment given their pleiotropic effect and their known clinical benefit in controlling SLE activity [2–4]. Additionally, HCQ/CQ have demonstrated cardiovascular benefits in patients with rheumatic diseases including SLE, by reducing cardiovascular risk factors and cardiovascular events in many observational studies [5].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness